Biodesix Inc (NASDAQ:BDSX)’s traded shares stood at 0.34 million during the last session, with the company’s beta value hitting 1.14. At the close of trading, the stock’s price was $1.35, to imply an increase of 3.05% or $0.04 in intraday trading. The BDSX share’s 52-week high remains $2.21, putting it -63.7% down since that peak but still an impressive 17.78% since price per share fell to its 52-week low of $1.11. The company has a valuation of $196.38M, with an average of 0.86 million shares in intraday trading volume over the past 10 days and average of 402.69K shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Biodesix Inc (BDSX), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give BDSX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.

Biodesix Inc (NASDAQ:BDSX) trade information

After registering a 3.05% upside in the last session, Biodesix Inc (BDSX) has traded red over the past five days. The 5-day price performance for the stock is -6.25%, and 1.50% over 30 days. With these gigs, the year-to-date price performance is -26.63%. Short interest in Biodesix Inc (NASDAQ:BDSX) saw shorts transact 0.39 million shares and set a 1.13 days time to cover.

The extremes give us $3 and $3 for target low and target high price respectively. As such, BDSX has been trading -122.22% off suggested target high and -122.22% from its likely low.

Biodesix Inc (BDSX) estimates and forecasts

Looking at statistics comparing Biodesix Inc share performance against respective industry, we note that the company has outperformed competitors. Biodesix Inc (BDSX) shares are 1.50% up over the last 6 months, with its year-to-date growth rate higher than industry average at 43.55% against 7.70%. The rating firms project that company’s revenue will grow 44.09% compared to the previous financial year.

Revenue forecast for the current quarter as set by 6 analysts is 19.83M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 20.22M.Earnings reports from the last fiscal year show that sales brought in 14.67M and 14.82M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 35.21% before jumping 36.46% in the following quarter.

BDSX Dividends

Biodesix Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Biodesix Inc (NASDAQ:BDSX)’s Major holders

Biodesix Inc insiders hold 48.62% of total outstanding shares, with institutional holders owning 42.83% of the shares at 83.35% float percentage. In total, 42.83% institutions holds shares in the company, led by TELEMARK ASSET MANAGEMENT, LLC. As of 2024-06-30, the company held over 8.28 million shares (or 8.5241% of shares), all amounting to roughly $12.67 million.

The next major institution holding the largest number of shares is SOLEUS CAPITAL MANAGEMENT, L.P. with 6.11 million shares, or about 6.2902% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $9.35 million.

We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Biodesix Inc (BDSX) shares. Going by data provided on Sep 30, 2024, Vanguard Total Stock Market Index Fund holds roughly 1.44 shares. This is just over 0.99% of the total shares, with a market valuation of $1.94 million. Data from the same date shows that the other fund manager holds a little less at 1.42, or 0.98% of the shares, all valued at about 1.92 million.